Walk through enough supplier pages and you'll see "GMP" and "research-grade" used as if they were two bins on the same shelf, one simply cleaner. They aren't comparable that way. One names a regulatory system; the other names a market segment. Everything on this page concerns material supplied for research use only — not for human or animal consumption of any kind — and the distinction between the terms is less about how pure a vial is than about what paperwork stands behind it, and who has assessed that paperwork.
"GMP" is one of the most-used and least-defined words in this corner of the chemical supply market, and knowing what it legally asserts is the difference between reading a product page accurately and misreading it. Below: what GMP is as a system, where the regulatory boundary falls, what a research-use-only label settles, what research-grade material still gets characterized for, and how the line shifts across clinical phases and borders.
What GMP Actually Means — It's a System, Not a Grade
The short answer: GMP is not an attribute of a vial. It's a documented quality system, assessed against a specific product.
That's not a pedantic correction — it comes straight out of the regulatory literature. A review of how GMP status gets determined for cell therapy products puts it plainly: GMP is "a product-specific assertion based on what is known about a product's relevant characteristics and a system of ensuring its quality," and compliance is "determined on a case-by-case, product-specific basis." The familiar shorthand of a facility simply being or not being "GMP-grade" obscures exactly that. No universal stamp travels with a powder.
The structural elements that define it
So what does the system consist of? Four things, roughly. Validated processes come first — and notably, FDA's own guidance states that neither "the CGMP regulations nor FDA policy specifies a minimum number of batches to validate a manufacturing process." The standard is demonstrated reproducibility, not a fixed count of successful runs. Second, an independent quality unit: management must maintain "a well-functioning quality system" with a unit holding real authority to reject a batch. Third, traceability — records that let the complete history of a batch be reconstructed afterward. Fourth, trained personnel documenting what they did, inside facilities with defined environmental controls.
Process-level claims versus single-lot results
For anyone comparing certificates, this is the distinction that pays off. ICH Q7, the harmonized standard for active pharmaceutical ingredients, expects "an impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process," listing each impurity's identity, observed range, and classification. Read that phrase carefully: produced by a specific controlled production process. The profile is tied to a validated, change-controlled process.
So a certificate of analysis documents what one lot contained. An ICH Q7 impurity profile documents what the process reproducibly produces. Only the second is a prediction. A single clean restaurant inspection tells you about one afternoon; a documented food-safety management system tells you something about next Tuesday. GMP is the second thing. How that reproducibility gets measured is its own subject — see our explainer on batch-to-batch consistency testing.
Where the Line Is Actually Drawn: 21 CFR 210/211 and Intended Use
The boundary isn't drawn around the molecule. It's drawn around what the material is for.
FDA's current good manufacturing practice requirements for human drugs live in 21 CFR Parts 210 and 211, and they contain "minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packing of a drug product." Part 210 covers manufacturing, processing, packing, and holding; Part 211 covers finished pharmaceuticals; Part 212 adds requirements for positron emission tomography drugs.
The words doing all the work are "drug product"
Parts 210 and 211 are scoped to drug products — material whose intended use is therapeutic use in humans or animals. Under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act, whether something is a drug turns on intended use. That's the hinge the whole comparison swings on, and everything else follows from it.
Material that isn't a drug product under the Act sits outside the scope of Parts 210 and 211. But "outside the scope of those parts" is not the same as unregulated, and it's certainly not the same as uncharacterized. The fuller treatment of how status gets assigned is in our piece on the intended-use doctrine.
Why "research-grade Semaglutide" is not the approved product
Compounds whose names are also INN or USAN drug names — Semaglutide, Tirzepatide, Retatrutide, BPC-157 — create a specific confusion worth naming directly. Research-grade material bearing one of these names is not equivalent to the FDA-approved pharmaceutical product of the same name. Same nominal sequence, entirely different regulatory object.